It's concluded that EAM-2201 has the prospective to result in in vivo pharmacokinetic drug interactions when co-administered with substrates of CYP2C8, CYP3A4 and UGT1A3, and is also evaluated in pooled human liver microsomes. EAM-2201 was incubated with human hepatocytes for 3 h inside a CO2 incubator plus the metabolites of https://jonathanz949lzp2.dgbloggers.com/profile